Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Erratum Free access | 10.1172/JCI73340

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

Aurélien Marabelle, Holbrook Kohrt, Idit Sagiv-Barfi, Bahareh Ajami, Robert C. Axtell, Gang Zhou, Ranjani Rajapaksa, Michael R. Green, James Torchia, Joshua Brody, Richard Luong, Michael D. Rosenblum, Lawrence Steinman, Hyam I. Levitsky, Victor Tse, and Ronald Levy

Find articles by Marabelle, A. in: JCI | PubMed | Google Scholar

Find articles by Kohrt, H. in: JCI | PubMed | Google Scholar

Find articles by Sagiv-Barfi, I. in: JCI | PubMed | Google Scholar

Find articles by Ajami, B. in: JCI | PubMed | Google Scholar

Find articles by Axtell, R. in: JCI | PubMed | Google Scholar

Find articles by Zhou, G. in: JCI | PubMed | Google Scholar

Find articles by Rajapaksa, R. in: JCI | PubMed | Google Scholar

Find articles by Green, M. in: JCI | PubMed | Google Scholar

Find articles by Torchia, J. in: JCI | PubMed | Google Scholar

Find articles by Brody, J. in: JCI | PubMed | Google Scholar

Find articles by Luong, R. in: JCI | PubMed | Google Scholar

Find articles by Rosenblum, M. in: JCI | PubMed | Google Scholar

Find articles by Steinman, L. in: JCI | PubMed | Google Scholar

Find articles by Levitsky, H. in: JCI | PubMed | Google Scholar

Find articles by Tse, V. in: JCI | PubMed | Google Scholar

Find articles by Levy, R. in: JCI | PubMed | Google Scholar

Published November 1, 2013 - More info

Published in Volume 123, Issue 11 on November 1, 2013
J Clin Invest. 2013;123(11):4980–4980. https://doi.org/10.1172/JCI73340.
© 2013 The American Society for Clinical Investigation
Published November 1, 2013 - Version history
View PDF

Related article:

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Aurélien Marabelle, … , Victor Tse, Ronald Levy
Aurélien Marabelle, … , Victor Tse, Ronald Levy
Research Article

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

  • Text
  • PDF
Abstract

Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, Tregs eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. In tumor-bearing mice, we found that Tregs within the tumor preferentially express the cell surface markers CTLA-4 and OX40. We show that intratumoral coinjection of anti–CTLA-4 and anti-OX40 together with CpG depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed with low doses of antibodies in a single tumor, generated a systemic antitumor immune response that eradicated disseminated disease in mice. Further, this treatment modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that are usually considered to be tumor cell sanctuaries in the context of conventional systemic therapy. These results demonstrate that antitumor immune effectors elicited by local immunomodulation can eradicate tumor cells at distant sites. We propose that, rather than using mAbs to target cancer cells systemically, mAbs could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response.

Authors

Aurélien Marabelle, Holbrook Kohrt, Idit Sagiv-Barfi, Bahareh Ajami, Robert C. Axtell, Gang Zhou, Ranjani Rajapaksa, Michael R. Green, James Torchia, Joshua Brody, Richard Luong, Michael D. Rosenblum, Lawrence Steinman, Hyam I. Levitsky, Victor Tse, Ronald Levy

×

Original citation: J. Clin. Invest. 2013;123(6):2447–2463. doi:10.1172/JCI64859.

Citation for this erratum: J. Clin. Invest. 2013;123(11):4980. doi:10.1172/JCI73340.

During the editing process, the survival curves in Figure 4G were mislabeled. The correct figure is below.

Figure 4

The JCI regrets the error.

Version history
  • Version 1 (November 1, 2013): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts